We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche and Sysmex Expand 25-Year Partnership to Foster More Sustainable Diagnostic Solutions

By LabMedica International staff writers
Posted on 04 Aug 2023
Print article
Image: Roche will continue to offer Sysmex hematology products based on the renewed terms (Photo courtesy of Sysmex)
Image: Roche will continue to offer Sysmex hematology products based on the renewed terms (Photo courtesy of Sysmex)

Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan) have expanded their Global Business Partnership Agreement. The renewed agreement reinforces the commitment of both companies to their long-established collaboration. Under the revised terms, Roche, which has been collaborating with Sysmex for 25 years, will continue to offer Sysmex's hematology products, complementing its comprehensive laboratory solutions portfolio. The Global Business Partnership Agreement between Roche and Sysmex promises to assist patients requiring diagnostic solutions and aims to enhance the efficiency and effectiveness of lab testing by offering integrated in-vitro diagnostics (IVD) technologies through a single provider.

The commercial and R&D collaboration between Roche and Sysmex was initiated in 1998, and the companies have since consistently strengthened their partnership. In 2020, both companies signed the Global Business Partnership Agreement to broaden their partnership further and enhance the customer experience. As of 2023, with updated terms and an expanded scope, both companies have reaffirmed their long-standing partnership and commitment to fostering a more sustainable future for society. The revised non-exclusive agreement ushers in a new dimension of cooperation, incorporating an additional eco-social agreement to jointly investigate more sustainable diagnostic solutions. By extending their long-standing collaboration beyond the current portfolio, both companies have demonstrated their commitment to seeking more sustainable solutions.

“We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions,” said Matt Sause, CEO of Roche Diagnostics. “Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow.”

“We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration,” added Kaoru Asano, President of Sysmex Corporation. “Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society."

Related Links:
Roche
Sysmex Corporation

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.